NASDAQ: PALIPalisade Bio Inc Stock
$0.78+0.02 (+2.63%)
Updated Apr 30, 2025
PALI Price
$0.78
Fair Value Price
N/A
Market Cap
$3.41M
52 Week Low
$0.60
52 Week High
$8.57
P/E
-0.08x
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$14.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.45
Operating Cash Flow
-$12M
Beta
1.07
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PALI Overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PALI's potential to beat the market
- PALI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PALI
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important PALI news, forecast changes, insider trades & much more!
PALI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PALI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PALI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PALI is good value based on its book value relative to its share price (0.46x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
PALI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PALI due diligence checks available for Premium users.
Valuation
PALI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.08x
Industry
-162.28x
Market
29.18x
PALI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.45x
PALI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PALI's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
PALI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.9M
Liabilities
$3.4M
Debt to equity
0.45
PALI's short-term assets ($10.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PALI's short-term assets ($10.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PALI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PALI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
$0.0
Financing
$4.2M
PALI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PALI vs Biotech Stocks
Palisade Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.